(Q37628708)

21 August 2017

1 reference

title

Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides (English)

1 reference

21 August 2017

3

Ulrich Bogdahn

1 reference

21 August 2017

1

Peter Hau

1 reference

21 August 2017

Piotr Jachimczak

2

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1663-1674

1 reference

Targeted therapy for malignant gliomas

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Antisense and/or immunostimulatory oligonucleotide therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Accessing the therapeutic potential of immunostimulatory nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

CpG DNA and LPS induce distinct patterns of activation in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Antisense anticancer oligonucleotide therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Toxicology of antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Making sense of latent TGFbeta activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

The two faces of transforming growth factor beta in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta signaling: positive and negative effects on tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Escaping from the TGFbeta anti-proliferative control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Vascular and perivascular GD3 expression in human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factor-betas in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Improving the delivery of therapeutic agents to CNS neoplasms: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

Modulation of the immune response by transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.138

21 January 2018

Identifiers

DOI

10.1586/ERA.09.138

1 reference

21 August 2017

1 reference